New England Journal of Medicine· 2020Q1· Clinical trial
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- 5,074citations
- Q1SCImago
- 2020year
Short summary
Empagliflozin significantly reduced the risk of cardiovascular death or hospitalization for worsening heart failure by 25% in patients with heart failure and reduced ejection fraction, regardless of diabetes status.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Endocrinology, Diabetes and Metabolism
Endocrinology, Diabetes and MetabolismMedicine